Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans

Vaccine

Volumn 35, Issue 42, 2017, Pages 5644-5652

  Tan, Shuguang ^a,d,e   Zhang, Shihong ^f   Wu, Bin ^b   Zhao, Yingze ^c   Zhang, Wei ^a   Han, Min ^a   Wu, Ying ^g   Shi, Guoli ^h   Liu, Yingxia ^e   Yan, Jinghua ^a,d,e   Wu, Guizhen ^c   Wang, Hua ^b   Gao, George F ^a,c,d,e,i   Zhu, Fengcai ^b   Liu, William J ^c,d  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b Jiangsu Provincial Centre for Disease Prevention and Control   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f USA   (United States)

^g WUHAN UNIVERSITY   (China)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

2009 pandemic influenza A (H1N1) virus; HA specific CD4+ T cell response; Split virus vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEMAGGLUTININ; HLA ANTIGEN; INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; INFECTION PREVENTION; INFLUENZA VACCINATION; LONGITUDINAL STUDY; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; NORMAL HUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SPLIT VACCINE INOCULATION; ADOLESCENT; ANTIBODY PRODUCTION; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); PROCEDURES; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 85029216407     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.08.061     Document Type: Article

References (49)

1. Hancock, K., Veguilla, V., Lu, X., Zhong, W., Butler, E.N., Sun, H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361 (2009), 1945–1952.
2. Rewar, S., Mirdha, D., Rewar, P., Treatment and prevention of pandemic H1N1 influenza. Ann Glob Health 81 (2015), 645–653.
3. Borse, R.T., Kadam, D.B., Sangle, S.A., Basavraj, A., Prasad, H.B., Umarji, P.B., et al. Clinicoradiologic correlation in adult patients diagnosed with novel influenza A (H1N1). J Assoc Phys India 61 (2013), 600–607.
4. Cao, B., Li, X.W., Mao, Y., Wang, J., Lu, H.Z., Chen, Y.S., et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 361 (2009), 2507–2517.
5. Liu, D., Shi, W., Shi, Y., Wang, D., Xiao, H., Li, W., et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet, 2013.
6. Zhang, Y., Zhang, Q., Kong, H., Jiang, Y., Gao, Y., Deng, G., et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340 (2013), 1459–1463.
7. Kong, W.L., Wang, F.B., Dong, B., Ou, C.B., Meng, D.M., Liu, J.H., et al. Novel reassortant influenza viruses between pandemic (H1N1) 2009 and other influenza viruses pose a risk to public health. Microb Pathogen 89 (2015), 62–72.
8. Le, T.B., Lee, I.H., Kim, B.J., Kim, H.S., Seo, S.H., Detection and pathogenesis of a novel swine H3N2 influenza virus containing three genes from the 2009 pandemic H1N1 influenza viruses in Korea in 2015. Virol Sin 31 (2016), 513–516.
9. Schotsaert, M., Garcia-Sastre, A., Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol 23 (2017), 102–106.
10. Gao, G.F.S.Y., It is not just AIV: from avian to swine-origin influenza virus. Sci China Life Sci 53:1 (2010), 151–153.
11. Zhang, W., Qi, J.X., Shi, Y., Li, Q., Gao, F., Sun, Y.P., et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 1 (2010), 459–467.
12. Wu, Y., Gao, G.F., Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: Live free markets and human health. Sci China-Life Sci 56 (2013), 493–494.
13. Zhu, F.C., Wang, H., Fang, H.H., Yang, J.G., Lin, X.J., Liang, X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 361 (2009), 2414–2423.
14. Shriver, Z., Trevejo, J.M., Sasisekharan, R., Antibody-based strategies to prevent and treat influenza. Front Immunol, 6, 2015, 315.
15. Wu, Y., Cho, M., Shore, D., Song, M., Choi, J., Jiang, T., et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun, 6, 2015, 7708.
16. Black, S., Nicolay, U., Vesikari, T., Knuf, M., Del Giudice, G., Della Cioppa, G., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30 (2011), 1081–1085.
17. Gravenstein, S., Drinka, P., Duthie, E.H., Miller, B.A., Brown, C.S., Hensley, M., et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 42 (1994), 245–251.
18. Mackenzie, C.D., Taylor, P.M., Askonas, B.A., Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunol 67 (1989), 375–381.
19. Sun, Y., Liu, J., Yang, M., Gao, F., Zhou, J., Kitamura, Y., et al. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol 91 (2010), 919–930.
20. Agrati, C., Gioia, C., Lalle, E., Cimini, E., Castilletti, C., Armignacco, O., et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 202 (2010), 681–689.
21. Wilkinson, T.M., Li, C.K., Chui, C.S., Huang, A.K., Perkins, M., Liebner, J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18 (2012), 274–280.
22. Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19 (2013), 1305–1312.
23. Sridhar S. Heterosubtypic T-Cell immunity to influenza in Humans: Challenges for Universal T-Cell influenza vaccines. Front Immunol. 2016; 7.
24. Bender, B.S., Croghan, T., Zhang, L., Small, P.A. Jr., Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175 (1992), 1143–1145.
25. Guo, H., Santiago, F., Lambert, K., Takimoto, T., Topham, D.J., T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85 (2011), 448–455.
26. Schotsaert, M., Saelens, X., Leroux-Roels, G., Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines 11 (2012), 949–962.
27. Subbramanian, R.A., Basha, S., Shata, M.T., Brady, R.C., Bernstein, D.I., Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28 (2010), 8258–8267.
28. Liu, J., Xiao, H., Wu, Y., Liu, D., Qi, X., Shi, Y., et al. H7N9: a low pathogenic avian influenza A virus infecting humans. Curr Opin Virol 5 (2014 Apr), 91–97.
29. Basta, S., Alatery, A., The cross-priming pathway: a portrait of an intricate immune system. Scand J Immunol 65 (2007), 311–319.
30. Garulli, B., Di Mario, G., Sciaraffia, E., Accapezzato, D., Barnaba, V., Castrucci, M.R., Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 31 (2013), 1717–1724.
31. Liu, J., Wu, B., Zhang, S., Tan, S., Sun, Y., Chen, Z., et al. Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations. Eur J Immunol 43 (2013), 2055–2069.
32. Zhou, M., Xu, D., Li, X., Li, H., Shan, M., Tang, J., et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 177 (2006), 2138–2145.
33. Li, X., Liu, J., Qi, J., Gao, F., Li, Q., Zhang, N., et al. Diverse peptide presentation of rhesus macaque MHC Cattle MHC Class I N*01801 (BoLA-A11): a Host Strategy to Present Featured Peptides. J Virol 85 (2011), 6038–6048.
34. Tan, S., Tan, X., Sun, X., Lu, G., Chen, C.C., Yan, J., et al. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol 191 (2013), 1637–1647.
35. Liu, J., Zhang, S., Tan, S., Yi, Y., Wu, B., Cao, B., et al. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol 86 (2012), 13281–13294.
36. Shao, L.N., Zhang, S.T., Yu, W.J., Zhou, S.H., Duan, Y., Pan, L.Z., et al. HLA-A, HLA-B, HLA-DRB1 allele and haplotype frequencies of 14,529 Chinese Han bone marrow donors living in Dalian, China. Int J Immunogenet 43 (2016), 79–85.
37. de Jong, J.C., Palache, A.M., Beyer, W.E., Rimmelzwaan, G.F., Boon, A.C., Osterhaus, A.D., Haemagglutination-inhibiting antibody to influenza virus. Dev Biologicals 115 (2003), 63–73.
38. Liang, X.F., Wang, H.Q., Wang, J.Z., Fang, H.H., Wu, J., Zhu, F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375 (2010), 56–66.
39. Chaloupka, I., Schuler, A., Marschall, M., Meier-Ewert, H., Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 15 (1996), 121–127.
40. Bevan, M.J., Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143 (1976), 1283–1288.
41. Pooley, J.L., Heath, W.R., Shortman, K., Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8(-) dendritic cells, but cross-presented to CD8 T cells by CD8(+) dendritic cells. J Immunol 166 (2001), 5327–5330.
42. Furuya, Y., Chan, J., Regner, M., Lobigs, M., Koskinen, A., Kok, T., et al. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J Virol 84 (2010), 4212–4221.
43. Hong, D.K., Chang, S., Botham, C.M., Giffon, T.D., Fairman, J., Lewis, D.B., Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 84 (2010), 12691–12702.
44. Subbramanian, R.A., Basha, S., Brady, R.C., Hazenfeld, S., Shata, M.T., Bernstein, D.I., Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum Immunol 71 (2010), 957–963.
45. Basha, S., Hazenfeld, S., Brady, R.C., Subbramanian, R.A., Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 72 (2011), 463–469.
46. He, X.S., Holmes, T.H., Sasaki, S., Jaimes, M.C., Kemble, G.W., Dekker, C.L., et al. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PloS One, 3, 2008, e2574.
47. Swain, S.L., McKinstry, K.K., Strutt, T.M., Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 12 (2012), 136–148.
48. Gras, S., Kedzierski, L., Valkenburg, S.A., Laurie, K., Liu, Y.C., Denholm, J.T., et al. Cross- reactive CD8(+) T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci USA 107 (2010), 12599–12604.
49. Liu, W.J., Tan, S., Zhao, M., Quan, C., Bi, Y., Wu, Y., et al. Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. J Infect Dis 214:12 (2016), 1937–1946.